Why the study?
Data were lacking regarding the effect of triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and azithromycin on corrected QT interval and arrhythmic risk in COVID-19 patients.
Does triple combination therapy with lopinavir-ritonavir, azithromycin, and hydroxychloroquine increase the risk of extreme QTc interval prolongation in hospitalized COVID-19 patients?
Does triple combination therapy with lopinavir-ritonavir, azithromycin, and hydroxychloroquine increase the risk of extreme QTc interval prolongation in hospitalized COVID-19 patients?
Triple combination therapy with lopinavir-ritonavir, hydroxychloroquine, and azithromycin in COVID-19 patients is associated with a high incidence (23%) of extreme QTc prolongation, necessitating careful electrocardiographic monitoring.
Answers are grounded in this paper and cite their sources.
Clinicians should monitor QTc on this COVID-19 regimen; leaves open arrhythmic risk and mitigation in randomized trials.
Introduction No data are provided about the effect of triple combination therapy with Lopinavir/Ritonavir (LPN/RTN), hydroxychloroquine (HQ) and azithromycin (AZT) on corrected QT (QTc) interval and arrhythmic risk, in COVID-19 patients. This study aims to describe the incidence of extreme QTc interval prolongation among COVID-19 patients on this experimental treatment and to identify the clinical features associated with extreme QTc prolongation. Materials and Methods Data of 87 COVID-19 patients, treated with triple combination including LPN/RTN, HQ and AZT, were analyzed. QT interval was obtained by the tangent method and corrected for heart rate using Bazett’s formula. Extreme QTc interval prolongation was considered an absolute QTc interval ≥ 500 ms or an increase in QTc intervals of 60 ms or greater (ΔQTc ≥ 60 ms) compared with baseline. Results Hypertension (66.7%) and diabetes (25.3%) were the most prevalent cardiovascular comorbidities. Twenty patients (23%) showed extreme QTc interval prolongation; no clinical, electrocardiographic or pharmacological characteristics have been associated to extreme QTc prolongation, except the history of ischemic stroke (P= 0,007). One torsade de pointes (TdP) in patient with QTc extreme prolongation (QTc: 560 ms) after 5 days of therapy was recorded. Conclusions We observed a high incidence of extreme QTc interval prolongation among COVID-19 patients on triple combination therapy. Since the incidence of malignant arrhythmias seems to be not negligible, a careful electrocardiographic monitoring would be advisable.
No takes yet. Share an insight, caveat, or question.
Russo et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: